Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Sun Pharma announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™

Posted On: 2019-06-14 13:38:10

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYATM (tildrakizumab-asmn) in patients with active psoriatic arthritis that was presented in a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain (abstract #LB-0002).1 The interim analysis revealed that over 71 percent of patients treated with ILUMYA™ experienced a 20 percent improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study. The interim results showed ILUMYA™ was well tolerated with a low rate of serious treatment-emergent adverse events.

ILUMYA™ is approved in the U.S. for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is being investigated for psoriatic arthritis. Psoriatic arthritis, which affects up to 42 percent of people with plaque psoriasis, is an inflammatory condition that impacts both the joints and skin. It is painful, causes fatigue, and can lead to swelling and stiffness of the joints that may reduce range of motion. If left untreated, this chronic condition can lead to permanent joint damage.2,3,4

"As a researcher and clinician, it's encouraging to see these improvements in pain, joint swelling and skin plaques. Our interim findings showed that about half of the patients treated with 100 mg or 200 mg of tildrakizumab saw a 50 percent improvement in psoriatic arthritis symptoms and about a quarter saw a 70 percent improvement within 24 weeks," said study investigator Philip J. Mease, MD, MACR, director of rheumatology research at the Swedish Medical Center/Providence St Joseph Health and clinical professor at the University of Washington School of Medicine, Seattle, WA. "These data insights are promising for patients who continue to struggle with the impact psoriatic arthritis has on their daily lives."

The Phase 2 study interim results showed that across all patients receiving ILUMYA™, 75.3 percent experienced a 20 percent improvement in symptoms of psoriatic arthritis (ACR20) at week 24 compared to 50.6 percent of patients on placebo. The findings were similar in patients receiving 100mg or 200 mg of ILUMYA™ on a quarterly dosing schedule. For some patients on 100 mg ILUMYA™, results were seen as early as 8 weeks. Furthermore, an average of 47.1 percent of all patients receiving ILUMYA™ achieved an ACR50 response with some results seen as early as 12 weeks, compared to 24.1 percent of patients on placebo.

The interim results also showed ILUMYA™ was well tolerated with a low and comparable rate of adverse events to placebo. Serious treatment-emergent adverse events occurred in 2.2 percent of patients treated with ILUMYA™ and 2.5 percent in those on placebo, with no patients discontinuing treatment due to these events. The most common adverse events through week 24 included common cold (nasopharyngitis), upper respiratory tract infection, and headache. There were no reports of candidiasis, inflammatory bowel disease, major adverse cardiac events, malignancy, or deaths.

"We are committed to the continued clinical development of ILUMYA™ and are pleased with the interim results in our first study for psoriatic arthritis," said Kyle Ferguson, Business Unit Head, Vice President Sales & Marketing, Sun Pharma. "To help us determine the potential of ILUMYA™ across psoriatic disease, we are now exploring a possible Phase 3 trial for psoriatic arthritis with regulatory authorities."

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.390.1 as compared to the previous close of Rs. 391.65. The total number of shares traded during the day was 193543 in over 2692 trades.

The stock hit an intraday high of Rs. 393.6 and intraday low of 385.7. The net turnover during the day was Rs. 75306141.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Sudarshan Chemical Industries Ltd board to approve first quarter results on Aug 7, 2019

Alkyl Amines Chemicals Ltd calls for board meeting on Aug 6, 2019

Torrent Power Ltd board to consider 1st quarter results on Aug 5, 2019

Shoppers Stop Ltd board to approve Q1 results on July 30, 2019

YES Bank Ltd reports net profit of Rs. 95.56 crores in Q1 FY20

OIL sign contract for the blocks awarded under OALP Bids Round II & III

MAGGI Fusian Noodles Records Overwhelming Sales On Amazon Prime Days

WIPRO Ltd Q1 FY20 consolidated PAT up YoY at Rs. 2387.6 crores

Mahanagar Gas Ltd board to consider Q1 results on Aug 8, 2019

Insecticides India Ltd board to announce first quarter results on Aug 2, 2019

Khadim India Ltd board to approve 1st quarter results on Aug 6, 2019

NMDC Ltd announces production and sales for June 2019

Ind-Ra updates on ratings of Rajkumar Forge Ltd

Menon Bearings Ltd Board declares Interim Dividend of Rs. 1.25

Jindal Stainless Limited clamps down on counterfeit market with a co-branding initiative

Aditya Birla Money Ltd Q1 PAT up at Rs. 3.49 crore

Rajratan Global Wire Ltd Board to consider Bonus Issue

Menon Bearings Ltd Q1 FY20 net profit slips to Rs. 4.73 crore

CARE Ratings Ltd Board to consider Q1 results & Dividend on July 31, 2019

Monsanto India Ltd board to announce quarterly results on July 24, 2019

Dhanlaxmi Bank Ltd reports net profit of Rs. 19.84 crores in Q1 FY20

Cera Sanitaryware LtdCera Sanitaryware Ltd board to consider Q1 results on Aug 1, 2019

TATA Elxsi Ltd Q1 FY20 net profit falls to Rs. 48.79 crore

L&T Construction led JV secures contract for 100 MLD Desalination Plant

LTI to Acquire Advanced Analytics Firm Lymbyc

Dilip Buildcon, Shaanxi JV emerges L1 bidder for new EPC project in Karnataka

Dilip Buildcon Ltd receives provisional completion certificate for section of NH-33 project

Brickwork revises NCD rating of Vodafone Idea Ltd

MCX's consolidated total income up by 30% to Rs. 110.84 crore in Q1 FY 2019-20

DCB Bank announces First Quarter FY 2020 Results

5paisa Capital - Income for Q1FY20 at Rs. 2,288 Lakhs

Zensar is a Gold sponsor at the ISG Automation Summit 2019, New York

Astron Paper & Board Mill Ltd updates on shut down of plant

Manaksia Ltd appoints Mr. Bharat Begwani as CFO

NTT Com-Netmagic Partners with Tata Power to Build 50 MW Solar Power Project

Agro Tech Foods Ltd reports Q1FY20 PAT of Rs. 7.02 crore

B C Power Controls Ltd Q1 net profit at Rs. 0.86 crore

Jay Bharat Maruti Ltd consolidated Q1 net profit slides to Rs. 7.84 crore

DCB Bank Ltd Q1 FY20 PAT at Rs. 81.06 crores

5paisa Capital Limited's rights issue to open for subscription on July 23, 2019

NMDC terminates BHEL contract

5paisa Capital Ltd reports consolidated loss of Rs. 0.52 crore in Q1

MCX Q1 FY20 consolidated PAT jumps YoY to Rs. 43.70 crores

Suzlon Energy defaults on payment of outstanding bonds

KNR Constructions Ltd receives work order for Rs. 847.34 crores

Deepak Nitrite Ltd board to approve Q1 results on Aug 2, 2019

CARE revises Commercial Paper rating of KRBL Ltd

Quartz™-powered TCS BaNCS™ Network Named Best Blockchain Breakthrough of the Year

South Indian Bank Ltd board to consider Q1 results on July 25, 2019

Vikas WSP Ltd bags order from UK for organic gluten free flour

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019